home / stock / imrx / imrx quote
Last: | $1.5177 |
---|---|
Change Percent: | -2.71% |
Open: | $1.59 |
Close: | $1.56 |
High: | $1.59 |
Low: | $1.5 |
Volume: | 39,965 |
Last Trade Date Time: | 05/10/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.5177 | $1.59 | $1.56 | $1.59 | $1.5 | 39,965 | 05-10-2024 |
$1.56 | $1.63 | $1.56 | $1.63 | $1.52 | 176,052 | 05-09-2024 |
$1.63 | $1.55 | $1.63 | $1.72 | $1.53 | 256,779 | 05-08-2024 |
$1.56 | $1.66 | $1.56 | $1.66 | $1.52 | 268,551 | 05-07-2024 |
$1.65 | $1.64 | $1.65 | $1.7783 | $1.58 | 315,097 | 05-06-2024 |
$1.64 | $1.73 | $1.64 | $1.73 | $1.6 | 340,551 | 05-03-2024 |
$1.56 | $1.55 | $1.56 | $1.63 | $1.51 | 313,063 | 05-02-2024 |
$1.53 | $1.46 | $1.53 | $1.6 | $1.38 | 951,574 | 05-01-2024 |
$1.42 | $1.49 | $1.42 | $1.58 | $1.39 | 573,287 | 04-30-2024 |
$1.48 | $1.49 | $1.48 | $1.53 | $1.38 | 596,728 | 04-29-2024 |
$1.47 | $1.43 | $1.47 | $1.51 | $1.43 | 295,784 | 04-26-2024 |
$1.43 | $1.53 | $1.43 | $1.5428 | $1.4 | 382,352 | 04-25-2024 |
$1.5 | $1.61 | $1.5 | $1.65 | $1.47 | 471,224 | 04-24-2024 |
$1.63 | $1.71 | $1.63 | $1.73 | $1.6 | 328,220 | 04-23-2024 |
$1.72 | $1.77 | $1.72 | $1.79 | $1.69 | 331,241 | 04-22-2024 |
$1.8 | $1.79 | $1.8 | $1.82 | $1.56 | 515,620 | 04-19-2024 |
$1.77 | $1.89 | $1.77 | $1.89 | $1.76 | 178,106 | 04-18-2024 |
$1.86 | $1.87 | $1.86 | $1.97 | $1.82 | 295,376 | 04-17-2024 |
$1.84 | $1.89 | $1.84 | $1.96 | $1.75 | 689,968 | 04-16-2024 |
$1.915 | $2.07 | $1.915 | $2.08 | $1.89 | 857,129 | 04-15-2024 |
News, Short Squeeze, Breakout and More Instantly...
Immuneering Corporation Company Name:
IMRX Stock Symbol:
NASDAQ Market:
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - ...
- Two clinical stage product candidates in development for the treatment of melanoma - - RAS mutant melanoma represents one of five arms in the company’s ongoing Phase 2a clinical study of IMM-1-104 - - Melanoma also being evaluated in ongoing Phase 1/2a clinical study of...
Resideo Technologies Inc. (REZI) is expected to report $0.33 for Q1 2024 Schneider National Inc. (SNDR) is expected to report $0.13 for Q1 2024 Murphy Oil Corporation (MUR) is expected to report $0.82 for Q1 2024 Astronics Corp. - Class B (ATROB) is expected to report for Q1 2024 ...